Search results for Gantenerumab
Gantenerumab Biosimilar – Anti-APP , Abeta42, Abeta40 mAb – Research Grade, ProteoGenix, PX-TA1158
Description of Gantenerumab Biosimilar - Anti-APP , Abeta42, Abeta40 mAb - Research Grade General information on Anti-APP /Abeta42/Abeta40(Homo sapiens) (Gantenerumab) Monoclonal Antibody Gantenerumab is under investigation for the treatment of Alzheimers Disease and targets IGF1 protein.
Host
Reactivity
Applications
Conjugation
Gantenerumab, Abbexa, abx831113
Gantenerumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting APP/Abeta42/Abeta40, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Gantenerumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Gantenerumab Biosimilar - Research Grade, ichor.bio, ICH5009
Detects human Beta Amyloid. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Gantenerumab.
Host
CHO cells
Reactivity
Human
Applications
Conjugation
Research Grade Gantenerumab (HY235036), abinScience, HY235036
Host
Human
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.